BTO (BTO) Stock Price & Analysis
BTO (BTO) rose 1.31% to USD 37.77 as of June 9, 2026 at 23:51 UTC, according to Nexqual real-time market data.
BTO last closed at USD 37.28; the session ranged USD 37.44–38 on volume of 57,618 shares. Market capitalization is —, with a 52-week range of USD 32.01–39.85 (NYQ). Source: Nexqual, June 9, 2026 at 23:51 UTC.
Key Statistics (as of June 9, 2026 at 23:51 UTC)
| Price | USD 37.77 |
|---|---|
| Change | ▲ 1.31% (up) |
| Previous Close | USD 37.28 |
| Open | USD 37.5 |
| Day Range | USD 37.44 – 38 |
| 52-Week Range | USD 32.01 – 39.85 |
| Volume | 57,618 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (BTO)
Nexqual's technical model rates BTO "BUY" based on 5 bullish and 2 bearish signals across 124 daily candles, as of June 9, 2026 at 23:51 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 61.84 (neutral) |
| vs SMA50 | Above (USD 36.78) |
| MACD | 0.15 (positive) |
Analyst Ratings (BTO)
Wall Street analysts rate BTO "None", per Nexqual as of June 9, 2026 at 23:51 UTC.
| Consensus Rating | None |
|---|
Earnings (BTO)
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financials & Fundamentals (BTO)
| Total Revenue | $26.21M |
|---|---|
| Revenue Growth (YoY) | -1.60% |
| Gross Margin | +100.00% |
| Operating Margin | +59.45% |
| Profit Margin | +267.14% |
| ROE | +9.94% |
| Debt / Equity | 18.2 |
| Current Ratio | 0.08 |
| Total Debt | $130.00M |
| Free Cash Flow | $3.22M |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Financial Health Score (BTO)
Nexqual rates BTO's overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:51 UTC.
| Growth | Weak — Revenue -2% YoY (latest Q), declining |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Solid — Debt/Equity 0.2x |
| Cash Flow | Solid — FCF $3M, 12% margin |
| Efficiency | Mixed — ROE 10%, ROA 1.2% |
Ownership (BTO)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +26.04% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Major Backers & Investors (BTO)
Notable institutional backers of BTO include Morgan Stanley, Wells Fargo & Company, Z3 Capital Partners, LLC, according to Nexqual as of June 9, 2026 at 23:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 6% |
| Wells Fargo & Company | 3.3% |
| Z3 Capital Partners, LLC | 2.06% |
| Royal Bank of Canada | 1.35% |
| Janney Montgomery Scott LLC | 0.97% |
| Raymond James Financial, Inc. | 0.9% |
| LPL Financial LLC | 0.65% |
| Stifel Financial Corporation | 0.52% |
Source: Nexqual, June 9, 2026 at 23:51 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| HQH | Tekla Healthcare Investors | USD 18.9 | ▼ 1.15% |
| RVT | Royce Value Trust, Inc. | USD 17.75 | ▲ 0.68% |
| ASG | Liberty All-Star Growth Fund, I | USD 5.25 | ▲ 0.96% |
| HQL | TeklaLife Sciences Investors | USD 16.78 | ▼ 0.83% |
| BME | Blackrock Health Sciences Trust | USD 40.48 | ▲ 1.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:51 UTC. This page is informational and not investment advice.